Overcoming Docetaxel Resistance in Prostate Cancer by Targeting Cell Cycle Progression with Narciclasine-Based Compounds
Development of resistance to taxane-based chemotherapy, specifically docetaxel (DTX), in advanced prostate cancer is frequent. Natural compounds, such as narciclasine, an alkaloid derived from plants, offer a potentially advantageous approach. Docetaxel-resistant prostate cancer cell lines (DU145RST and PC3RST) were es...